66 results
8-K
EX-3.2
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
and qualified.
B. STOCKHOLDER ACTIONS. No action shall be taken by the stockholders of the Company except at an annual or special meeting of stockholders
8-K
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
. On December 13, 2023, Neoleukin’s stockholders approved the 2023 EIP at the Special Meeting (as defined below) and on December 18, 2023, the newly … at the Special Meeting and on December 18, 2023, the Board ratified the 2023 ESPP. The purpose of the 2023 ESPP is to enable eligible employees of the Company
8-K
EX-3.3
9ocsug3zduvijcbjb
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
S-4/A
e1v ku7htjt8
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
CORRESP
equnt69g34ha2
28 Sep 23
Correspondence with SEC
12:00am
UPLOAD
jnwcnv7hm 1ipx4jnu
18 Sep 23
Letter from SEC
12:00am
S-4
c3g261 24
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
8-K
EX-3.1
up3n8db8
30 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:46pm
424B5
imbj6u9wd kq2u
4 Nov 21
Prospectus supplement for primary offering
4:55pm